IMGN Stock Overview
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
ImmunoGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.75 |
| 52 Week High | US$6.63 |
| 52 Week Low | US$3.10 |
| Beta | 0.89 |
| 1 Month Change | -4.23% |
| 3 Month Change | -15.48% |
| 1 Year Change | -15.93% |
| 3 Year Change | 1.50% |
| 5 Year Change | -44.31% |
| Change since IPO | -42.42% |
Recent News & Updates
Recent updates
What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates
Jan 03
New Forecasts: Here's What Analysts Think The Future Holds For ImmunoGen, Inc. (NASDAQ:IMGN)
Nov 17We Think ImmunoGen (NASDAQ:IMGN) Needs To Drive Business Growth Carefully
Oct 17We're Keeping An Eye On ImmunoGen's (NASDAQ:IMGN) Cash Burn Rate
Jul 03Companies Like ImmunoGen (NASDAQ:IMGN) Are In A Position To Invest In Growth
Feb 27Here's Why We're Not Too Worried About ImmunoGen's (NASDAQ:IMGN) Cash Burn Situation
Nov 13Shareholders May Not Be So Generous With ImmunoGen, Inc.'s (NASDAQ:IMGN) CEO Compensation And Here's Why
Jun 10Does ImmunoGen (NASDAQ:IMGN) Have A Healthy Balance Sheet?
Mar 13Need To Know: Analysts Are Much More Bullish On ImmunoGen, Inc. (NASDAQ:IMGN) Revenues
Feb 15
Can You Imagine How ImmunoGen's (NASDAQ:IMGN) Shareholders Feel About The 48% Share Price Increase?
Jan 29How Much Of ImmunoGen, Inc. (NASDAQ:IMGN) Do Institutions Own?
Dec 07Shareholder Returns
| IMGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.9% | 0.8% | 2.8% |
| 1Y | -15.9% | 7.1% | -9.2% |
Return vs Industry: IMGN underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: IMGN underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| IMGN volatility | |
|---|---|
| IMGN Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IMGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: IMGN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 106 | Mark Enyedy | https://www.immunogen.com |
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate.
ImmunoGen, Inc. Fundamentals Summary
| IMGN fundamental statistics | |
|---|---|
| Market Cap | US$1.05b |
| Earnings (TTM) | -US$201.09m |
| Revenue (TTM) | US$95.61m |
11.0x
P/S Ratio-5.2x
P/E RatioIs IMGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMGN income statement (TTM) | |
|---|---|
| Revenue | US$95.61m |
| Cost of Revenue | US$203.85m |
| Gross Profit | -US$108.25m |
| Other Expenses | US$92.85m |
| Earnings | -US$201.09m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | -113.22% |
| Net Profit Margin | -210.33% |
| Debt/Equity Ratio | 0% |
How did IMGN perform over the long term?
See historical performance and comparison